Market Intelligence, Clinical Progress, and High-Purity Reagents for Asthma and Atopic Dermatitis Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-13Ra1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-13Ra1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View IL13RA1 Products |
| Gene Delivery | IL-13Ra1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and signaling assays. |
View IL13RA1 Products |
| Benchmark Ab | Anti-IL-13Ra1 Recombinant Antibody Recombinant positive control for binding and blocking assays. |
View IL13RA1 Products |
| Validator | IL-13Ra1 siRNA Set For target knockdown verification and specificity controls. |
View IL13RA1 Products |
| Related Target A | IL-13 Primary ligand. Essential for receptor-ligand binding kinetics and functional blocking assays. |
View IL13 Products |
| Related Target B | IL-4Ralpha Heterodimerization partner. Required to reconstitute the high-affinity Type II IL-4/IL-13 receptor complex. |
View IL4R Products |
| Related Target C | IL-13Ra2 Decoy receptor. Crucial for counter-screening to ensure therapeutic selectivity and avoid off-target profiles. |
View IL13RA2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimerization validation (IL-13Ra1 + IL-4Ralpha) | Highly stable recombinant ECD proteins of both subunits with verified theoretical MW and native glycosylation. |
| Decoy receptor selectivity screening (IL-13Ra1 vs IL-13Ra2) | Homolog panel featuring sequence-verified IL-13Ra1 and IL-13Ra2 proteins to rule out off-target binding. |
| Cross-species reactivity assessment | Human, Cynomolgus, and Mouse ortholog proteins available with >95% purity determined by SDS-PAGE. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA sets included for target-specific knockdown verification. |
Live IL-13Ra1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-13Ra1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific and multispecific modalities that simultaneously target IL-13Ra1/IL-4Ralpha or IL-13/IL-31 pathways. As first-generation therapies targeting the ligands (such as Lebrikizumab and Tralokinumab) establish their clinical presence, the next wave of R&D is targeting the receptor subunits directly to achieve complete pathway blockade and overcome ligand-sink resistance mechanisms in severe Type 2 inflammatory diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies | Sanofi, Regeneron, AnaptysBio | Asthma, Atopic Dermatitis, COPD | Ligand-blocking assays (Requires high-purity, native-glycosylated ECD-Fc proteins). |
| Bispecific Antibodies | AstraZeneca, Roche, Amgen | Severe Asthma, Prurigo Nodularis | Co-binding and heterodimerization assays (Requires stable IL-13Ra1 and IL-4Ralpha/IL-31RA proteins). |
| Lentiviral Cell Lines | Academic & Biotech Consortia | Fibrotic Diseases, Esophagitis | Cell-based signaling and FACS screening (Requires high-titer Lentivirus for stable expression). |